Loading
A phase 2 trial of Firicabtagene autoleucel run by CARGO Therapeutics, terminated.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma is a phase 2 interventional study registered as NCT05972720 by CARGO Therapeutics, with 101 participants enrolled, started 2023-08-01. Conditions recorded: Cancer and Relapsed/Refractory Large B-cell Lymphoma (LBCL). Interventions recorded: Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy) and firi-cel (Experimental drug).
Shares CARGO Therapeutics and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/